Clinical Research Directory
Browse clinical research sites, groups, and studies.
4SCAR-T Therapy Post CD19-targeted Immunotherapy
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Official title: 4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia
Key Details
Gender
All
Age Range
6 Months - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-06-01
Completion Date
2030-12-31
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20
Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
Locations (1)
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, China